Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRINKLE: Selumetinib Granule Formulation in Children With NF1 Related Plexiform Neurofibromas
NCT05309668Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2022
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of selumetinib in neurofibromatosis type 1 (NF1), sponsored by AstraZeneca. Started Jan 2022; status: active, not recruiting.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 1 (NF1)
Beyond the preview
Go deeper on NCT05309668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05309668.